Dostarlimab for Advanced Cancer
(GARNET Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing dostarlimab, a medicine that helps the immune system fight cancer, in patients with advanced solid tumors who have limited treatment options. It works by blocking a protein that allows cancer cells to hide from the immune system. Dostarlimab has garnered extensive interest for its ability to activate the immune system to respond to cancer cells.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it mentions that participants should not have received certain anti-cancer therapies or immunosuppressive treatments shortly before starting the trial. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drug Dostarlimab for advanced cancer?
Dostarlimab has shown promising results in treating certain types of advanced cancers, particularly endometrial cancer, where it has been approved for use in patients with specific genetic markers. In a clinical trial, it achieved a 100% remission rate for rectal cancer, indicating its potential effectiveness in matching treatment to the genetic drivers of tumors.12345
Is dostarlimab safe for humans?
Dostarlimab has been tested in clinical trials, such as the GARNET study, to evaluate its safety and side effects in treating certain types of cancer, including endometrial cancer. The FDA has granted accelerated approval for its use, indicating that it has been deemed safe enough for specific conditions, but ongoing studies are required to confirm its long-term safety.12467
How is the drug dostarlimab unique for treating advanced cancer?
Dostarlimab is unique because it is a monoclonal antibody that targets the PD-1 receptor, helping the immune system attack cancer cells, and it has shown promising results in treating cancers with specific genetic features, like mismatch repair deficiency, which are often resistant to other treatments.12347
Eligibility Criteria
Adults with advanced solid tumors and limited treatment options can join this trial. They must have specific tumor types, adequate organ function, and an ECOG performance status of <=2 for Part 1 or <=1 for Part 2. Women must not be pregnant and agree to use contraception. Participants cannot have had more than three prior cancer therapies.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab
Cohort Expansion
Evaluation of safety and clinical activity of dostarlimab in specific cohorts with advanced solid tumors
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Dostarlimab (Monoclonal Antibodies)
Dostarlimab is already approved in European Union, United States for the following indications:
- Mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer
- dMMR/MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen
- Adults with dMMR recurrent or advanced solid tumors who have progressed on or following prior treatment and lack satisfactory alternative treatment options
- Primary advanced or recurrent dMMR endometrial cancer in combination with carboplatin and paclitaxel